VR Logo

Omeros Corporation (OMER) download report


Healthcare | Biotechnology & Pharma Research

Omeros Corporation (OMER) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders.

IPO Date: 08-Oct-2009

Co-Founder, Chairman, CEO & Pres: Dr. Gregory A. Demopulos M.D.

Chief Accounting Officer, VP of Fin. & Treasurer: Mr. Michael A. Jacobsen

Listing: NASDAQ: OMER

Country: United States

Headquarters: Seattle, WA

Website: https://www.omeros.com

Key Facts

Market cap: $197.96 Mln

Revenue (TTM): $-21.06 Mln

Earnings (TTM): $196.31 Mln

Cash: $142.23 Mln

Total Debt: $342.13 Mln

Insider's Holding: 4.03%

Liquidity: Low

52 Week range: $1.86 - 16.57

Shares outstanding: 62,730,000

10 Years Aggregate:

  • CFO: $-648.85 Mln
  • EBITDA: $-799.81 Mln
  • Net Profit: $-502.30 Mln

Stock Performance

Time Period Omeros (OMER) S&P BSE Sensex* S&P Small-Cap 600*
YTD-58.63-8.99-19.22
1 month-2.21-3.40-9.34
3 months-55.81-8.50-14.58
1 Year-82.700.89-17.64
3 Years-44.6510.415.91
5 Years-33.4311.435.64
10 Years-12.6911.7710.10
As on 29-Jun-2022 *As on 30-Jun-2022
Year Omeros (OMER) S&P Small-Cap 600 S&P BSE Sensex
2021-54.9925.2721.99
20201.389.5715.75
201926.4820.8614.38
2018-42.49-9.705.87
201795.8711.7327.91
2016-36.9424.741.95
2015-36.52-3.36-5.03